396 related articles for article (PubMed ID: 21719262)
1. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry prior to I-131-therapy of benign thyroid disease.
Hänscheid H; Lassmann M; Reiners C
Z Med Phys; 2011 Dec; 21(4):250-7. PubMed ID: 21531122
[TBL] [Abstract][Full Text] [Related]
4. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
6. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
7. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
8. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
Moka D; Voth E; Schicha H
Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
[TBL] [Abstract][Full Text] [Related]
9. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
[TBL] [Abstract][Full Text] [Related]
10. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
[TBL] [Abstract][Full Text] [Related]
11. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
[TBL] [Abstract][Full Text] [Related]
12. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
[TBL] [Abstract][Full Text] [Related]
13. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
[TBL] [Abstract][Full Text] [Related]
14. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
15. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
16. Optimized dose planning of radioiodine therapy of benign thyroidal diseases.
Bockisch A; Jamitzky T; Derwanz R; Biersack HJ
J Nucl Med; 1993 Oct; 34(10):1632-8. PubMed ID: 8410273
[TBL] [Abstract][Full Text] [Related]
17. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
18. Pretherapeutic dosimetry before 131I therapy of benign thyroid disease. A clinical practice assessment of dosimetric parameters.
Krohn T; Behrendt FF; Heinzel A; Müller B; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(3):131-6. PubMed ID: 25487217
[TBL] [Abstract][Full Text] [Related]
19. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy for thyroid volume reduction of large goitres.
Bachmann J; Kobe C; Bor S; Rahlff I; Dietlein M; Schicha H; Schmidt M
Nucl Med Commun; 2009 Jun; 30(6):466-71. PubMed ID: 19381116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]